Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma (STRATUS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01712789|
Recruitment Status : Active, not recruiting
First Posted : October 24, 2012
Last Update Posted : June 29, 2018
The primary purpose of the study is to evaluate the safety and efficacy and to generate PK and biomarker data for the combination of pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma.
The study consists of a Screening phase within 28 days prior to cycle 1 day 1, a Treatment phase and a Follow-up phase which starts within 28 days of discontinuation from study treatment, every 3 months for up to 5 years.
In addition, the collection of steady-state PK data from a large population will enable robust population PK and assess Pomalidomide exposure response analyses.
The exploratory objectives of the study are to investigate potential markers predictive of POM response or resistance and pharmacodynamic markers.
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: Pomalidomide Drug: Dexamethasone||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||682 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter, Single-arm, Open-label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma|
|Actual Study Start Date :||November 6, 2012|
|Estimated Primary Completion Date :||December 11, 2019|
|Estimated Study Completion Date :||December 11, 2019|
Experimental: Pomalidomide plus Dexamethasone
Pomalidomide 4mg by mouth (PO) daily days 1 through 21 of a 28 day cycle and dexamethasone 40mg/day PO for those ≤75 years of age or 20mg/day for those greater than 75 years of age on Days 1, 8, 15 and 22 of a 28 day cycle.
Oral Pomalidomide at the starting dose of 4 mg on Days 1-21 of a 28-day cycle
Oral Low dose Dexamethasone at the starting dose of 40mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
- Adverse Events [ Time Frame: Up to 5 years ]Number of participants with adverse events
- PK-Cmax [ Time Frame: Up to 5 years ]PK-Maximum Concentration in Plasma
- PK-AUC [ Time Frame: Up to 5 years ]PK-Area under the plasma concentration time curve
- PK-Cmin [ Time Frame: Up to 5 years ]PK-Minimum Concentration in Plasma
- Overall response rate [ Time Frame: Up to 5 years ]Rate of participants who responds to the study treatment
- Time to response [ Time Frame: Up to 5 years ]Time from study enrollment to first documented response
- Duration of response [ Time Frame: Up to 5 years ]Time from the treatment response until progression of Multiple Myeloma
- Progression-free survival [ Time Frame: Up to 5 years ]Time from enrollment until progression of Multiple Myeloma
- Time to progression [ Time Frame: Up to 5 years ]Time from study enrollment until progression to Multiple Myeloma
- Overall survival [ Time Frame: Up to 5 years ]Time from study enrollment to the death of the patient
- POM population pharmacokinetics and exposure-response [ Time Frame: During the first 6 cycles of treatment ]The key exposure data are serum drug concentration, Cmax, Cmin and AUC derived from the population PK analysis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01712789
Show 112 Study Locations
|Study Director:||Tsvetan Biyukow, MD||Celgene|